GFG Capital’s Biogen BIIB Stock Holding History

GFG Capital’s Portfolio BIIB Stock Details BIIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-16	Closed	-$2.01K	–	93
2025 Q2	$2.01K	Buy	+16	New	+$1.99K	﹤0.01%	316

Other funds holding BIIB

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

GFG Capital's BIIB Position: Q3 2025 in Review

GFG Capital sold out of Biogen (BIIB) in Q3 2025, closing a stake of 16 shares — an estimated $2.01K sold.

GFG Capital first reported a position in BIIB in Q2 2025 and held it in 1 quarter. The position peaked at $2.01K in Q2 2025. 905 funds tracked by Wall St. Rank hold BIIB as of Q3 2025.

GFG Capital reported no remaining Biogen position as of Q3 2025 after selling out during the quarter.
GFG Capital sold 16 Biogen shares in Q3 2025, an estimated $2.01K.
GFG Capital first reported a position in Biogen in Q2 2025 and held it in 1 quarter.
GFG Capital's Biogen position peaked at $2.01K in Q2 2025.
905 funds tracked by Wall St. Rank held Biogen as of Q3 2025.

Based on GFG Capital's 13F filing for Q3 2025, filed 7 Oct 2025.